404 related articles for article (PubMed ID: 35428210)
21. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [
Buteau JP; Moon D; Fahey MT; Roberts MJ; Thompson J; Murphy DG; Papa N; Mitchell C; De Abreu Lourenco R; Dhillon HM; Kasivisvanathan V; Francis RJ; Stricker P; Agrawal S; O'Brien J; McVey A; Sharma G; Levy S; Ayati N; Nguyen A; Lee SF; Pattison DA; Sivaratnam D; Frydenberg M; Du Y; Titus J; Lee ST; Ischia J; Jack G; Hofman MS; Emmett L
Eur Urol Oncol; 2024 Jun; 7(3):544-552. PubMed ID: 38061976
[TBL] [Abstract][Full Text] [Related]
22. Treatment Outcomes from
Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
[No Abstract] [Full Text] [Related]
23. 3-Year Freedom from Progression After
Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
[No Abstract] [Full Text] [Related]
24. Failure Patterns by PSMA PET for Recurrent Prostate Cancer after Prostatectomy and Salvage Radiation.
Imber BS; O'Dwyer E; Lobaugh S; McBride SM; Hopkins M; Kollmeier M; Gorovets D; Brennan V; Pike LRG; Gewanter R; Mychalczak B; Zhang Z; Schöder H; Zelefsky MJ
Urology; 2022 Dec; 170():146-153. PubMed ID: 36115426
[TBL] [Abstract][Full Text] [Related]
25. Presurgical
Djaïleb L; Armstrong WR; Thompson D; Gafita A; Farolfi A; Rajagopal A; Grogan TR; Nguyen K; Benz MR; Hotta M; Barbato F; Ceci F; Schwarzenböck SM; Unterrainer M; Zacho HD; Juarez R; Cooperberg M; Carroll P; Washington S; Reiter RE; Eiber M; Herrmann K; Fendler WP; Czernin J; Hope TA; Calais J
Eur Urol; 2023 Dec; 84(6):588-596. PubMed ID: 37482512
[TBL] [Abstract][Full Text] [Related]
26. PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial.
Petit C; Delouya G; Taussky D; Barkati M; Lambert C; Beauchemin MC; Clavel S; Mok G; Paré AG; Nguyen TV; Duplan D; Keu KV; Saad F; Juneau D; Ménard C
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):779-787. PubMed ID: 36639035
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of
Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
[TBL] [Abstract][Full Text] [Related]
28. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
[TBL] [Abstract][Full Text] [Related]
29. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
30. Changes in Management After
Ng M; Guerrieri M; Wong LM; Taubman K; Sutherland T; Benson A; Byrne G; Koschel S; Yap K; Starmans M; Ong G; Macleod C; Foo M; Chao M
J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320
[TBL] [Abstract][Full Text] [Related]
31. Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial.
Park G; Kim YJ; Ahn H; Park W; Lee JS; Kim YS
Trials; 2021 Oct; 22(1):728. PubMed ID: 34674739
[TBL] [Abstract][Full Text] [Related]
32. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
33. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
34.
Sonni I; Dal Pra A; O'Connell DP; Ells Z; Benz M; Nguyen K; Yoon SM; Deng J; Smith C; Grogan T; Nickols NG; Cao M; Kishan AU; Calais J
J Nucl Med; 2023 Jun; 64(6):902-909. PubMed ID: 36759200
[TBL] [Abstract][Full Text] [Related]
35.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
36. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
39. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1015-1024. PubMed ID: 35659629
[TBL] [Abstract][Full Text] [Related]
40. Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
Roberts MJ; Chatfield MD; Hruby G; Nandurkar R; Roach P; Watts JA; Cusick T; Kneebone A; Eade T; Ho B; Nguyen A; Tang C; McCarthy M; Francis R; Stricker P; Emmett L
BJU Int; 2022 Nov; 130 Suppl 3(Suppl 3):32-39. PubMed ID: 35488182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]